Robotics to Be the Driving Force Behind J & amp;J ’s Device Unit

Johnson &Johnson is offering a preview of its surgical robotics strategy  May 13th during its Medical Device Business Review Day in New York. Executives of the New Brunswick, NJ-based company announced the date during a call discussing its 4Q19 results on Wednesday. Alex Gorsky, J&J’s CEO noted that going forward surgical robotics would be a driving force behind the company’s medtech division. “As it relates to medical devices, we've been, I think, very consistent in sharing our thinking that, again, this next generation is certainly about the robotics component that helps facilitate perhaps having more consistency in an exact procedure, perhaps getting into a tighter space, having better access,” Gorsky said, according to a Seeking Alpha transcript of the earnings call. The news follows the healthcare giant buying out Verily’s interest in the Verb Surgical joint venture for an undisclosed sum. The Verb buyout is one of two major developments that occurred last year that are set to power J&J’s upcoming surgical robotics platform. The second development is J&J’s acquisition of Auris Health. Redwood City, CA-based Auris Health develops robotic technologies that have been focused on lung cancer. The firm has the Monarch Platform, an FDA-cleared system currently used in bronchoscopic diagnostic and therapeutic procedures. Gorsky...
Source: MDDI - Category: Medical Devices Authors: Tags: Digital Health Source Type: news

Related Links:

Drs West and Aggarwal share their thoughts on the past decade's targeted therapy innovations, and how they may keep going well into the 2020s.Medscape Oncology
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
Conclusion: Our study reveals that miR-206 functions as a tumor metastasis suppressor and sheds new light on the clinical significance of miR-206 in NSCLC therapy. PMID: 32206066 [PubMed - in process]
Source: Cellular and Molecular Biology Letters - Category: Biochemistry Authors: Tags: Cell Mol Biol Lett Source Type: research
(H. Lee Moffitt Cancer Center&Research Institute) Researchers at Moffitt Cancer Center are trying to identify alternative strategies to treat non-small cell lung cancer (NSCLC). In a new article published online in Scientific Reports, they highlight how targeting the histone deacetylase HDAC11 may be a novel therapeutic strategy for NSCLC.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
AbstractMalnutrition and systemic inflammation are associated with poor outcomes in patients with heart failure. Recent studies have reported that the advanced lung cancer inflammation index (ALI), derived from the body mass index (BMI), serum albumin level, and neutrophil-to-lymphocyte ratio (NLR), is associated with poor prognosis in several types of cancers. Each marker is also known to prognostic factor of heart failure. Therefore, we hypothesized that ALI may be useful for determining the prognosis of patients with acute decompensated heart failure (ADHF). We reviewed survival in 381 consecutive patients (age, 73.1 &t...
Source: Heart and Vessels - Category: Cardiology Source Type: research
hristina R. Bellinger Chemo-immunotherapy is central to the treatment of small cell lung cancer (SCLC). Despite modest progress made with the addition of immunotherapy, current cytotoxic regimens display minimal survival benefit and new treatments are needed. Thymidylate synthase (TS) is a well-validated anti-cancer drug target, but conventional TS inhibitors display limited clinical efficacy in refractory or recurrent SCLC. We performed RNA-Seq analysis to identify gene expression changes in SCLC biopsy samples to provide mechanistic insight into the potential utility of targeting pyrimidine biosynthesis to treat SCLC...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
In this study we analyzed and validated the cytogenetic alterations that arise after treatment in four lung and ovarian paired cisplatin-sensitive/resistant cell lines by 1-million microarray-based comparative genomic hybridization (array-CGH) and qRT-PCR methodologies. RNA-sequencing, functional transfection assays, and gene-pathway activity analysis were used to identify genes with a potential role in the development of this malignancy. The results were further explored in 55 lung and ovarian primary tumors and control samples, and in two extensive in silico databases. Long-term cell exposure to platinum induces the freq...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ong Jin Hyoung Kang Epidermal growth factor receptor (EGFR) mutation testing is essential for individualized treatment using tyrosine kinase inhibitors. We evaluated two EGFR mutation tests, cobas v2 and PANAMutyper, for detection of EGFR activating mutations Ex19del, L858R, and T790M in tumor tissue and plasma from 244 non-small cell lung cancer (NSCLC) patients. The Kappa coefficient (95% CI) between the tests was 0.82 (0.74–0.92) in tumor samples (suggesting almost perfect agreement) and 0.69 (0.54–0.84) in plasma (suggesting substantial agreement). In plasma samples, both tests showed low to m...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Brief Report Source Type: research
Carboplatin plus pemetrexed followed by maintenance pemetrexed is an effective alternative to docetaxel monotherapy for elderly patients with advanced nonsquamous non-small cell lung cancer (NSCLC), researchers in Japan report.Reuters Health Information
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
AbstractAnaplastic lymphoma kinase (ALK) rearrangements have been reported in 5% to 6% of non ‐small cell lung cancer (NSCLC) patients. However, the concurrent existence of twoALK fusions within the same patient have rarely previously been reported. Moreover, considering the diversities ofALK mutations, it is necessary to evaluate the response of both double and new types ofALK fusions to ALK ‐tyrosine kinase inhibitors (ALK‐TKIs). Here, we report a case of a 64‐year‐old Chinese woman who was diagnosed with lung adenocarcinoma (ADC) who concurrently harbored two types ofALK‐rearrangements, including an unreport...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
ConclusionsAmong patients with lung adenocarcinoma in stage I, those with ACN have a better OS and LCSS than that with PAP. For patients with stage I ACN, Seg and Lob, rather than Wed, seem to be an equivalent treatment choice; however, Seg is the prior option because it could preserve more lung function than Lob. For patients with PAP, Lob tends to be a better choice than Wed and Seg, although the prognostic difference between them is nonsignificant.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
More News: Bronchoscopy | Cancer | Cancer & Oncology | Lung Cancer | Lung Transplant | Medical Devices | Mergers and Aquisitions | Orthopaedics | Partnerships